Market Summary
USD268.98-0.06
Market Closed-0.02%
AMGN Stock Price
AMGN RSI Chart
AMGN Valuation
AMGN Price/Sales (Trailing)
AMGN Profitability
AMGN Fundamentals
AMGN Revenue
AMGN Earnings
Price Action
52 Week Range
211.71292.06
(Low)(High)
Last 7 days
-0.9%
Last 30 days
4.9%
Last 90 days
21.6%
Trailing 12 Months
20.9%
AMGN Financial Health
AMGN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for AMGN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-10 | Gordon Murdo | sold | -2,508,310 | 262 | -9,558 | evp, global commercial ops |
2023-08-08 | ISHRAK OMAR | acquired | - | - | 124 | - |
2023-08-08 | Drake Michael V | acquired | - | - | 124 | - |
2023-08-08 | HOLLEY CHARLES M | acquired | - | - | 153 | - |
2023-07-31 | Grygiel Nancy A. | sold (taxes) | -266,862 | 236 | -1,129 | svp & cco |
2023-05-19 | Kullman Ellen Jamison | acquired | - | - | 939 | - |
2023-05-19 | ISHRAK OMAR | acquired | - | - | 939 | - |
2023-05-19 | SUGAR RONALD D | acquired | - | - | 939 | - |
2023-05-19 | Garland Greg C. | acquired | - | - | 939 | - |
2023-05-19 | Austin Wanda M | acquired | - | - | 939 | - |
Which funds bought or sold AMGN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-26 | BROOKFIELD Corp /ON/ | reduced | -53.21 | -332,943 | 250,883 | -% |
2023-09-26 | M Holdings Securities, Inc. | sold off | -100 | -545,000 | - | -% |
2023-09-21 | Baystate Wealth Management LLC | added | 3.64 | -21,774 | 429,772 | 0.04% |
2023-09-21 | Jefferies Group LLC | added | 3,672 | 16,526,300 | 17,013,200 | 0.14% |
2023-09-20 | BARCLAYS PLC | added | 111 | 181,867,000 | 375,254,000 | 0.24% |
2023-09-18 | CAPE ANN SAVINGS BANK | new | - | 213,361 | 213,361 | 0.14% |
2023-09-14 | IMS Capital Management | added | 66.11 | 295,007 | 856,396 | 0.48% |
2023-09-14 | Proquility Private Wealth Partners, LLC | added | 0.08 | -70,654 | 804,934 | 0.32% |
2023-09-13 | CGC Financial Services, LLC | new | - | 11,101 | 11,101 | 0.01% |
2023-09-12 | Farther Finance Advisors, LLC | added | 74.29 | 163,904 | 436,566 | 0.10% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Amgen
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.01% | 48,065,139 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 9.1% | 48,513,079 | SC 13G/A | |
| Feb 06, 2023 | state street corp | 5.58% | 29,760,088 | SC 13G/A | |
| Feb 11, 2022 | capital research global investors | 3.9% | 22,157,906 | SC 13G/A | |
| Feb 10, 2022 | state street corp | 5.37% | 30,221,708 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.28% | 46,661,009 | SC 13G/A | |
| Feb 01, 2022 | blackrock inc. | 8.9% | 50,046,345 | SC 13G/A | |
| Feb 16, 2021 | capital research global investors | 5.5% | 31,762,327 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.11% | 47,227,229 | SC 13G/A | |
| Feb 05, 2021 | state street corp | 5.17% | 30,113,284 | SC 13G |
Recent SEC filings of Amgen
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 27, 2023 | SC 13D | 13D - Major Acquisition | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 14, 2023 | 3 | Insider Trading | |
| Sep 12, 2023 | 8-K | Current Report | |
| Sep 05, 2023 | 8-K | Current Report | |
| Sep 01, 2023 | 8-K | Current Report | |
| Aug 21, 2023 | 3 | Insider Trading | |
| Aug 11, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading | |
| Aug 10, 2023 | 4 | Insider Trading |
AMGN Fair Value
Loading...
Peers (Alternatives to Amgen)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 143.9B | 26.6B | 4.85% | 20.90% | 18.03 | 5.41 | 0.75% | 21.34% |
GILD | 94.2B | 27.4B | -1.93% | 22.79% | 17.18 | 3.44 | -0.48% | 32.56% |
MRNA | 37.9B | 10.7B | -12.64% | -18.65% | 31.39 | 3.56 | -53.67% | -91.41% |
BIIB | 37.3B | 10.0B | -2.84% | 30.20% | 13.98 | 3.74 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.3B | 1.7B | 8.03% | 13.91% | 63.88 | 6.74 | 29.01% | 1345.90% |
BBIO | 4.3B | - | -8.13% | 165.26% | -7.28 | 48.33 | 54.84% | -12.96% |
DNLI | 3.0B | - | -5.45% | -21.11% | -23.04 | 37.44 | 122.90% | 54.78% |
BEAM | 1.9B | 80.2M | 3.54% | -49.89% | -5.78 | 23.59 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.4B | 121.2M | -13.83% | -27.58% | -4.86 | 11.52 | -70.36% | -531.73% |
REPL | 979.0M | 15.3M | -20.35% | -0.54% | -5.39 | 63.94 | 1090.59% | -36.57% |
NVAX | 678.1M | 1.6B | -13.89% | -64.12% | -1.16 | 0.42 | 23.74% | 60.24% |
FATE | 206.9M | - | -21.05% | -90.40% | -0.98 | 1.51 | 116.83% | 16.61% |
VXRT | 109.6M | 2.1M | -12.14% | -66.77% | -1.09 | 53.32 | 487.70% | -8.66% |
SGMO | 104.5M | - | -28.14% | -88.04% | -0.53 | 0.43 | 113.96% | -15.19% |
IBIO | 3.6M | - | -8.13% | -96.28% | -0.05 | 3.21 | - | -129.46% |
Amgen News
Returns for AMGN
Cumulative Returns on AMGN
11.9%
10-Year Cumulative Returns
9.9%
7-Year Cumulative Returns
8.4%
5-Year Cumulative Returns
6.3%
3-Year Cumulative Returns
Risks for AMGN
What is the probability of a big loss on AMGN?
28.1%
Probability that Amgen stock will be more than 20% underwater in next one year
0%
Probability that Amgen stock will be more than 30% underwater in next one year.
0%
Probability that Amgen stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does AMGN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Amgen was unfortunately bought at previous high price.
Drawdowns
Financials for Amgen
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.5% | 26,582 | 26,190 | 26,323 | 26,330 | 26,384 | 26,316 | 25,979 | 25,767 | 25,484 | 25,164 | 25,424 | 24,987 | 24,301 | 23,966 | 23,362 | 23,395 | 23,562 | 23,750 | 23,747 | 23,319 | 23,188 |
| Costs and Expenses | -0.7% | 17,087 | 17,203 | 16,757 | 16,690 | 17,026 | 18,306 | 18,340 | 18,424 | 18,066 | 16,251 | 16,285 | 15,808 | 15,099 | 14,409 | 13,688 | 13,387 | 13,707 | 13,741 | 13,484 | 13,193 | 12,946 |
| S&GA Expenses | -0.6% | 5,411 | 5,444 | 5,414 | 5,267 | 5,285 | 5,342 | 5,368 | 5,716 | 5,757 | 5,668 | 5,730 | 5,470 | 5,347 | 5,312 | 5,150 | 5,196 | 5,266 | 5,359 | 5,332 | 5,200 | 5,077 |
| EBITDA | -100.0% | - | 14,243 | 12,169 | 12,413 | 12,117 | 11,124 | 11,296 | 11,046 | 11,154 | 12,716 | 12,996 | 12,914 | 12,603 | 12,744 | 12,633 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.54* | 0.46* | 0.47* | 0.46* | 0.42* | 0.43* | 0.43* | 0.44* | 0.51* | 0.51* | 0.52* | 0.52* | 0.53* | 0.54* | - | - | - | - | - | - |
| Interest Expenses | 25.6% | 2,078 | 1,654 | 1,406 | 1,326 | 1,254 | 1,207 | 1,197 | 1,180 | 1,186 | 1,201 | 1,262 | 1,245 | 1,256 | 1,292 | 1,289 | 1,340 | 1,382 | 1,397 | 1,392 | 1,372 | 1,342 |
| Earnings Before Taxes | 0.9% | 9,196 | 9,113 | 7,346 | 7,729 | 7,492 | 6,519 | 6,701 | 6,447 | 6,498 | 7,970 | 8,133 | 8,239 | 8,310 | 8,844 | 9,138 | 9,340 | 9,157 | 9,240 | 9,545 | 9,574 | 9,861 |
| EBT Margin | -100.0% | - | 0.35* | 0.28* | 0.29* | 0.28* | 0.25* | 0.26* | 0.25* | 0.25* | 0.32* | 0.32* | 0.33* | 0.34* | 0.37* | 0.39* | - | - | - | - | - | - |
| Net Income | 0.8% | 7,979 | 7,917 | 6,552 | 6,835 | 6,576 | 5,723 | 5,893 | 5,609 | 5,746 | 7,085 | 7,264 | 7,352 | 7,299 | 7,675 | 7,842 | 8,067 | 7,958 | 8,075 | 8,394 | 2,202 | 2,364 |
| Net Income Margin | -100.0% | - | 0.30* | 0.25* | 0.26* | 0.25* | 0.22* | 0.23* | 0.22* | 0.23* | 0.28* | 0.29* | 0.29* | 0.30* | 0.32* | 0.34* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 7,531 | 8,785 | 8,997 | 8,355 | 8,417 | 8,381 | 7,840 | 8,897 | 9,835 | 9,889 | 10,235 | 10,209 | 8,795 | 8,532 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 1.7% | 90,269 | 88,720 | 65,121 | 63,700 | 59,294 | 59,196 | 61,165 | 64,993 | 59,773 | 62,539 | 62,948 | 64,637 | 65,011 | 61,669 | 59,707 | 59,535 | 59,373 | 63,997 | 66,416 | 67,333 | 67,684 |
| Current Assets | 6.0% | 47,380 | 44,703 | 22,186 | 24,062 | 19,322 | 18,520 | 19,385 | 24,380 | 19,099 | 21,299 | 21,144 | 22,661 | 22,895 | 18,813 | 18,440 | 31,051 | 30,746 | 35,151 | 37,618 | 38,320 | 37,970 |
| Cash Equivalents | 8.5% | 34,248 | 31,560 | 7,629 | 9,502 | 5,203 | 6,528 | 7,989 | 11,969 | 6,630 | 6,112 | 6,266 | 9,087 | 9,145 | 7,687 | 6,037 | 11,415 | 5,525 | 7,358 | 6,945 | 11,956 | 10,131 |
| Inventory | -0.7% | 4,978 | 5,011 | 4,930 | 4,757 | 4,554 | 4,411 | 4,086 | 4,152 | 4,115 | 4,017 | 3,893 | 3,942 | 3,840 | 3,682 | 3,584 | 3,243 | 3,176 | 3,016 | 2,940 | 3,017 | 3,063 |
| Net PPE | 1.3% | 5,532 | 5,460 | 5,427 | 5,188 | 5,158 | 5,142 | 5,184 | 4,982 | 4,906 | 4,855 | 4,889 | 4,816 | 4,843 | 4,879 | 4,928 | 4,901 | 4,882 | 4,892 | 4,958 | 4,899 | 4,922 |
| Goodwill | 0% | 15,531 | 15,531 | 15,529 | 14,845 | 14,865 | 14,897 | 14,890 | 14,665 | 14,676 | 14,673 | 14,689 | 14,674 | 14,678 | 14,683 | 14,703 | 14,705 | 26.00 | 14,692 | 14,699 | 14,684 | 14,724 |
| Current Liabilities | 20.3% | 17,097 | 14,215 | 15,687 | 14,331 | 12,618 | 12,886 | 12,184 | 14,842 | 14,585 | 12,869 | 11,653 | 9,953 | 10,523 | 11,827 | 12,835 | 10,737 | 10,622 | 12,706 | 13,488 | 12,432 | 11,205 |
| LT Debt, Current | 159.8% | 2,167 | 834 | 1,591 | 1,543 | 817 | 844 | 87.00 | 4,288 | 4,324 | 1,556 | 91.00 | 91.00 | 91.00 | 1,840 | 2,953 | 2,049 | 2,816 | 3,705 | 4,419 | 5,077 | 4,288 |
| LT Debt, Non Current | -2.3% | 59,377 | 60,761 | 37,354 | 37,161 | 35,705 | 36,010 | 33,222 | 33,291 | 28,458 | 31,129 | 32,895 | 34,196 | 34,133 | 30,008 | 26,950 | 27,742 | 27,798 | 29,319 | 29,510 | 29,350 | 30,209 |
| Shareholder's Equity | 26.8% | 6,781 | 5,348 | 3,661 | 3,653 | 2,419 | 916 | 6,700 | 8,217 | 8,247 | 9,334 | 9,409 | 10,959 | 10,659 | 9,485 | 9,673 | 10,927 | 10,794 | 10,832 | 12,500 | 14,349 | 14,909 |
| Retained Earnings | 5.1% | -25,540 | -26,919 | -28,622 | -28,066 | -28,252 | -29,568 | -24,600 | -22,964 | -22,762 | -21,639 | -21,408 | -19,851 | -20,168 | -21,378 | -21,330 | -20,136 | -20,054 | -19,895 | -17,977 | -15,987 | -15,266 |
| Shares Outstanding | 0.1% | 535 | 534 | 534 | 534 | 535 | 548 | 558 | 567 | 573 | 577 | 578 | 585 | 588 | 590 | 591 | 599 | 607 | 622 | 630 | 645 | 656 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | 25.3% | 10,800 | 8,621 | 9,721 | 9,880 | 9,320 | 9,321 | 9,261 | 8,606 | 9,556 | 10,467 | 10,497 | 10,858 | 10,867 | 9,439 | 9,150 | 9,830 | 9,726 | 10,414 | 11,296 | 11,114 | 11,295 |
| Share Based Compensation | - | - | - | 401 | - | - | - | 341 | - | - | - | 330 | - | - | - | 308 | - | - | - | 311 | 309 | 320 |
| Cashflow From Investing | 43.3% | -2,593 | -4,575 | -6,044 | -2,801 | -2,461 | 941 | 733 | -421 | -2,122 | -5,490 | -5,401 | -9,980 | -2,980 | 1,924 | 5,709 | 7,035 | 2,795 | 2,988 | 14,339 | 18,898 | 15,790 |
| Cashflow From Financing | -0.7% | 20,838 | 20,986 | -4,037 | -9,546 | -8,286 | -9,846 | -8,271 | -5,303 | -9,949 | -6,552 | -4,867 | -3,206 | -4,267 | -11,034 | -15,767 | -17,406 | -17,127 | -15,785 | -22,490 | -21,056 | -19,583 |
| Dividend Payments | 2.4% | 4,354 | 4,253 | 4,196 | 4,146 | 4,107 | 4,077 | 4,013 | 3,955 | 3,892 | 3,826 | 3,755 | 3,683 | 3,615 | 3,553 | 3,509 | 3,489 | 3,472 | 3,457 | 3,507 | 3,501 | 3,488 |
| Buy Backs | -100.0% | - | 50.00 | 6,360 | 7,803 | 8,872 | 10,414 | 4,975 | 4,731 | 4,414 | 3,413 | 3,486 | 3,370 | 3,788 | 5,546 | 7,702 | 8,674 | 9,217 | 10,058 | 17,794 | 16,479 | 15,575 |
AMGN Income Statement
2023-06-30Condensed Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 6,986 | $ 6,594 | $ 13,091 | $ 12,832 |
| Operating expenses: | ||||
| Cost of sales | 1,813 | 1,510 | 3,533 | 3,071 |
| Research and development | 1,113 | 1,039 | 2,171 | 1,998 |
| Selling, general and administrative | 1,294 | 1,327 | 2,552 | 2,555 |
| Other | 82 | 542 | 230 | 532 |
| Total operating expenses | 4,302 | 4,418 | 8,486 | 8,156 |
| Operating income | 2,684 | 2,176 | 4,605 | 4,676 |
| Interest expense, net | (752) | (328) | (1,295) | (623) |
| Other (expense) income, net | (318) | (317) | 1,746 | (847) |
| Income before income taxes | 1,614 | 1,531 | 5,056 | 3,206 |
| Provision for income taxes | 235 | 214 | 836 | 413 |
| Net income | $ 1,379 | $ 1,317 | $ 4,220 | $ 2,793 |
| Earnings per share: | ||||
| Basic (in usd per share) | $ 2.58 | $ 2.46 | $ 7.90 | $ 5.16 |
| Diluted (in usd per share) | $ 2.57 | $ 2.45 | $ 7.86 | $ 5.13 |
| Shares used in calculation of earnings per share: | ||||
| Basic (in shares) | 535 | 535 | 534 | 541 |
| Diluted (in shares) | 537 | 537 | 537 | 544 |
| Product sales | ||||
| Revenues: | ||||
| Total revenues | $ 6,683 | $ 6,281 | $ 12,529 | $ 12,012 |
| Other revenues | ||||
| Revenues: | ||||
| Total revenues | $ 303 | $ 313 | $ 562 | $ 820 |
AMGN Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 34,248 | $ 7,629 |
| Marketable securities | 0 | 1,676 |
| Trade receivables, net | 5,830 | 5,563 |
| Inventories | 4,978 | 4,930 |
| Other current assets | 2,324 | 2,388 |
| Total current assets | 47,380 | 22,186 |
| Property, plant and equipment, net | 5,532 | 5,427 |
| Intangible assets, net | 14,633 | 16,080 |
| Goodwill | 15,531 | 15,529 |
| Other noncurrent assets | 7,193 | 5,899 |
| Total assets | 90,269 | 65,121 |
| Current liabilities: | ||
| Accounts payable | 1,212 | 1,572 |
| Accrued liabilities | 13,718 | 12,524 |
| Current portion of long-term debt | 2,167 | 1,591 |
| Total current liabilities | 17,097 | 15,687 |
| Long-term debt | 59,377 | 37,354 |
| Long-term tax liabilities | 4,478 | 5,757 |
| Other noncurrent liabilities | 2,536 | 2,662 |
| Contingencies and commitments | ||
| Stockholders’ equity: | ||
| Common stock and additional paid-in capital; $0.0001 par value; 2,750.0 shares authorized; outstanding—534.9 shares in 2023 and 534.0 shares in 2022 | 32,601 | 32,514 |
| Accumulated deficit | (25,540) | (28,622) |
| Accumulated other comprehensive loss | (280) | (231) |
| Total stockholders’ equity | 6,781 | 3,661 |
| Total liabilities and stockholders’ equity | $ 90,269 | $ 65,121 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.